AFT and Setek sign supply agreement

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com





Market and media release 4
th
November 2020
AFT and Setek sign supply agreement
Agreement covers pharmaceutical-grade medicinal cannabis ingredients for
products initially targeted for Australia and New Zealand

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) and medicinal cannabis company SETEK
today announce an agreement which will see SETEK provide Good Manufacturing
Practice (GMP) quality pharmaceutical-grade medicinal cannabis ingredients to
AFT.
It follows the two companies signing a memorandum of understanding (MOU) in
October 2019 to work together in the research, development, and commercialisation
of medicinal cannabis products.
The agreement envisages AFT selling medicinal cannabis products into selected,
markets starting with Australia and New Zealand. The timing of the launches of these
products is confidential and will be advised at a later date.
AFT Managing Director Hartley Atkinson said: “We are delighted to further advance
our working relationship with SETEK to bring medicinal cannabis products to market.
“SETEK’s international relationships and its understanding of medicinal cannabis
markets both in New Zealand and offshore make it and ideal partner for AFT.
“We have carefully studied the Australasian market and the required strategies to
commercialise a new set of medicinal cannabis products.
“This research has strengthened our view that these are a natural extension to the AFT
product portfolio. They have the potential to benefit from our extensive distribution
networks and to further strengthen AFT’s proposition with healthcare providers.
SETEK Chief Executive David Pearce said AFT is uniquely placed to bring medicinal
cannabis products to markets in New Zealand, Australia and further afield in markets
where AFT already has distribution and licensing partners.
“AFT’s understanding of pharmaceutical markets, the regulatory and commercial
hurdles and its record of commercial success make it a leader in Australasia and an
emerging player in the pharmaceutical market globally.
“The next step of our business collaboration following on from the MOU has now been
actioned with the signing of this agreement,” Mr Pearce said.

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial
Officer.
For more information:
Investors: Media:
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets and
distributes a broad portfolio of pharmaceutical products across a wide range of
therapeutic categories which are distributed across all major pharmaceutical
distribution channels: over-the-counter (OTC), prescription and hospital. Our product
portfolio comprises both proprietary and in-licensed products, and includes patented,
branded and generic drugs. Our business model is to develop and in-license products
for sale by our own dedicated sales teams in our home markets of Australia and New
Zealand and in certain Southeast Asian markets, and to out-license our products to
local licensees and distributors to over 125 countries around the world. For more
information about the company, visit our website www.aftpharm.com
.
About SETEK
SETEK is a 100% New Zealand-owned and operated company based in Taupo in the
central North Island of New Zealand. Our purpose is to help improve the quality of
people’s lives through the cultivation, processing and manufacture of GMP grade,
pure cannabis-based medicines and skincare products, produced in beautiful
Aotearoa New Zealand.